Literature DB >> 20185096

Tuberculosis and air travel: a systematic review and analysis of policy.

Ibrahim Abubakar1.   

Abstract

WHO international guidelines for the control of tuberculosis in relation to air travel require-after a risk assessment-tracing of passengers who sat for longer than 8 h in rows adjacent to people with pulmonary tuberculosis who are smear positive or smear negative. A further recommendation is that all commercial air travel should be prohibited until the person has two consecutive negative sputum smears for drug-susceptible tuberculosis or two consecutive cultures for multidrug-resistant tuberculosis. In this Review I examine the evidence put forward to support these recommendations and assess whether such an approach is justifiable. A systematic review identified 39 studies of which 13 were included. The majority of studies found no evidence of transmission. Only two studies reported reliable evidence of transmission. The analysis suggests that there is reason to doubt the value of actively screening air passengers for infection with Mycobacterium tuberculosis and that the resources used might be better spent addressing other priorities for the control of tuberculosis. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20185096     DOI: 10.1016/S1473-3099(10)70028-1

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  11 in total

1.  Economics of United States tuberculosis airline contact investigation policies: a return on investment analysis.

Authors:  Margaret S Coleman; Karen J Marienau; Nina Marano; Suzanne M Marks; Martin S Cetron
Journal:  Travel Med Infect Dis       Date:  2013-11-08       Impact factor: 6.211

2.  Boarding issue in a commercial flight for patients with cavitary pulmonary tuberculosis: A case report.

Authors:  Woori Jo; Chuiyong Pak; Yangjin Jegal; Kwang Won Seo
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

3.  Ending tuberculosis in risk groups in Europe: challenges from travel and population movement.

Authors:  Charlotte Jackson; Ibrahim Abubakar
Journal:  Euro Surveill       Date:  2017-03-23

4.  Tuberculosis contact investigations associated with air travel in Ireland, September 2011 to November 2014.

Authors:  Paula Flanagan; Joan O'Donnell; Jolita Mereckiene; Darina O'Flanagan
Journal:  Euro Surveill       Date:  2016-10-06

5.  Risk of tuberculosis among air passengers estimated by interferon gamma release assay: survey of contact investigations, Japan, 2012 to 2015.

Authors:  Masaki Ota; Seiya Kato
Journal:  Euro Surveill       Date:  2017-03-23

6.  Contact investigation after a fatal case of extensively drug-resistant tuberculosis (XDR-TB) in an aircraft, Germany, July 2013.

Authors:  Maria An der Heiden; Barbara Hauer; Lena Fiebig; Gisela Glaser-Paschke; Markus Stemmler; Claudia Simon; Sabine Rüsch-Gerdes; Andreas Gilsdorf; Walter Haas
Journal:  Euro Surveill       Date:  2017-03-23

7.  International tuberculosis contact-tracing notifications in Germany: analysis of national data from 2010 to 2018 and implications for efficiency.

Authors:  Saskia Glasauer; Stefan Kröger; Walter Haas; Nita Perumal
Journal:  BMC Infect Dis       Date:  2020-04-06       Impact factor: 3.090

8.  Research questions and priorities for tuberculosis: a survey of published systematic reviews and meta-analyses.

Authors:  Ioana Nicolau; Daphne Ling; Lulu Tian; Christian Lienhardt; Madhukar Pai
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

9.  Airborne biological hazards and urban transport infrastructure: current challenges and future directions.

Authors:  Zaheer Ahmad Nasir; Luiza Cintra Campos; Nicola Christie; Ian Colbeck
Journal:  Environ Sci Pollut Res Int       Date:  2016-06-18       Impact factor: 4.223

10.  Impact of global change on transmission of human infectious diseases.

Authors:  XiaoXu Wu; HuaiYu Tian; Sen Zhou; LiFan Chen; Bing Xu
Journal:  Sci China Earth Sci       Date:  2013-06-23       Impact factor: 4.368

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.